Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$9.67 USD
+0.15 (1.52%)
Updated May 13, 2024 04:00 PM ET
After-Market: $9.66 -0.01 (-0.10%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PHAT 9.67 +0.15(1.52%)
Will PHAT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PHAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHAT
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
Zacks.com featured highlights include Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies
PHAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Top Breakout Stocks Worth a Buy for Attractive Returns
Does Phathom Pharmaceuticals, Inc. (PHAT) Have the Potential to Rally 81.38% as Wall Street Analysts Expect?
Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Other News for PHAT
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript
Craig-Hallum Remains a Buy on Phathom Pharmaceuticals (PHAT)
The 3 Best Healthcare Stocks to Buy in May 2024
Wall Street Analysts Are Bullish on Top Healthcare Picks
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024